CD8A and neoplasm: We first assessed four previously established immunotherapy biomarkers (Interferon [IFN]-γ signature, CD8 score, tumor mutation burden [TMB], and tumor neoantigen burden [TNB])47 (Supplementary table 5) and found none of them significantly correlated with HRD for OS or PFS across cancer types (Supplementary Fig. 4), suggesting that the variation in PD-L1 predictiveness between different cancer types is probably not attributed to the level of other predictive biomarkers.